Causative role of PDLIM2 epigenetic repression in lung cancer and therapeutic resistance
PDLIM2 is repressed epigenetically in lung cancers, which are frequently resistant to anti-PD-1/PD-L1 and chemotherapy. Here, the authors describe the mechanism through which epigenetic restoration of PDLIM2 synergises with anti-PD-1 and chemotherapy in lung cancers.
Main Authors: | Fan Sun, Liwen Li, Pengrong Yan, Jingjiao Zhou, Steven D. Shapiro, Gutian Xiao, Zhaoxia Qu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2019-11-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-019-13331-x |
Similar Items
-
PDLIM2 repression by ROS in alveolar macrophages promotes lung tumorigenesis
by: Liwen Li, et al.
Published: (2021-03-01) -
PDLIM2 restricts Th1 and Th17 differentiation and prevents autoimmune disease
by: Qu Zhaoxia, et al.
Published: (2012-06-01) -
Human T-Cell Leukemia Virus Type I-Mediated Repression of PDZ-LIM Domain-Containing Protein 2 Involves DNA Methylation But Independent of the Viral Oncoprotein Tax
by: Pengrong Yan, et al.
Published: (2009-10-01) -
An Overview of the Cytoskeleton-Associated Role of PDLIM5
by: Xiaolan Huang, et al.
Published: (2020-08-01) -
PDLIM1: Structure, function and implication in cancer
by: Jian-Kang Zhou, et al.
Published: (2021-07-01)